Pancancer Landscape of Long Non-coding RNA Expression and Immune Status of the Tumor Microenvironment in Japanese Cancer Patients.

IF 1.7 4区 医学 Q4 ONCOLOGY
Tomoatsu Ikeya, Yasuto Akiyama, Haruo Miyata, Tadashi Ashizawa, Yasufumi Kikuchi, Akira Iizuka, Chie Maeda, Akari Kanematsu, Kazue Yamashita, Kenichi Urakami, Takeshi Nagashima, Keiichi Ohshima, Ken Yamaguchi
{"title":"Pancancer Landscape of Long Non-coding RNA Expression and Immune Status of the Tumor Microenvironment in Japanese Cancer Patients.","authors":"Tomoatsu Ikeya, Yasuto Akiyama, Haruo Miyata, Tadashi Ashizawa, Yasufumi Kikuchi, Akira Iizuka, Chie Maeda, Akari Kanematsu, Kazue Yamashita, Kenichi Urakami, Takeshi Nagashima, Keiichi Ohshima, Ken Yamaguchi","doi":"10.21873/anticanres.17782","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Advances in whole-genome sequencing have revealed that many RNA genes have important functions in various cellular processes and long non-coding RNAs (lncRNAs) have been attracting increasing attention. In the present study, we characterized a large number of lncRNAs from cancer patients and classified them based on their relationships with immune response-associated genes and cancer prognosis.</p><p><strong>Materials and methods: </strong>435 lncRNAs were identified as differentially expressed genes from 5,013 cancer patients using the <i>limma</i> package and were narrowed down to 80 lncRNAs commonly expressed in more than 4 cancer types. The relationships of these lncRNAs with immune response-associated genes were examined using Pearson's correlation and the tumor immune scoring system. Through a receiver operating characteristic (ROC) analysis of highly scored lncRNAs with the tumor-infiltrating lymphocyte (TIL) status using QuanTIseq, a cancer prognostic analysis was conducted using a multivariate Cox proportional hazards model.</p><p><strong>Results: </strong>In a correlation analysis of 80 lncRNA genes and immune response-associated genes, lncRNA genes were scored and classified as high, intermediate, and low immune status score groups based on the Tumor Immune Status Scoring Algorithm (TIMMUSCORA). The ROC analysis of lncRNA genes with a high score (>200) revealed high sensitivity for the identification of TILs, such as CD8<sup>+</sup> T cells and B cells. Furthermore, 11 of 80 lncRNA genes were identified as prognostic genes.</p><p><strong>Conclusion: </strong>Twelve lncRNA genes with a high immune status score were identified as immunogenic and CD8<sup>+</sup> T cell infiltration-associated genes, with two being indicators of a positive cancer prognosis. These results indicate the potential of 12 lncRNA genes with a high immune status score as immunogenic biomarkers associated with a positive immune response and prognosis.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 10","pages":"4315-4331"},"PeriodicalIF":1.7000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17782","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background/aim: Advances in whole-genome sequencing have revealed that many RNA genes have important functions in various cellular processes and long non-coding RNAs (lncRNAs) have been attracting increasing attention. In the present study, we characterized a large number of lncRNAs from cancer patients and classified them based on their relationships with immune response-associated genes and cancer prognosis.

Materials and methods: 435 lncRNAs were identified as differentially expressed genes from 5,013 cancer patients using the limma package and were narrowed down to 80 lncRNAs commonly expressed in more than 4 cancer types. The relationships of these lncRNAs with immune response-associated genes were examined using Pearson's correlation and the tumor immune scoring system. Through a receiver operating characteristic (ROC) analysis of highly scored lncRNAs with the tumor-infiltrating lymphocyte (TIL) status using QuanTIseq, a cancer prognostic analysis was conducted using a multivariate Cox proportional hazards model.

Results: In a correlation analysis of 80 lncRNA genes and immune response-associated genes, lncRNA genes were scored and classified as high, intermediate, and low immune status score groups based on the Tumor Immune Status Scoring Algorithm (TIMMUSCORA). The ROC analysis of lncRNA genes with a high score (>200) revealed high sensitivity for the identification of TILs, such as CD8+ T cells and B cells. Furthermore, 11 of 80 lncRNA genes were identified as prognostic genes.

Conclusion: Twelve lncRNA genes with a high immune status score were identified as immunogenic and CD8+ T cell infiltration-associated genes, with two being indicators of a positive cancer prognosis. These results indicate the potential of 12 lncRNA genes with a high immune status score as immunogenic biomarkers associated with a positive immune response and prognosis.

日本肿瘤患者长链非编码RNA表达与肿瘤微环境免疫状态的研究
背景/目的:全基因组测序的进展揭示了许多RNA基因在各种细胞过程中具有重要功能,长链非编码RNA (lncRNAs)越来越受到人们的关注。在本研究中,我们对来自癌症患者的大量lncrna进行了表征,并根据其与免疫反应相关基因和癌症预后的关系对其进行了分类。材料和方法:利用limma包从5013例癌症患者中鉴定出435个lncrna为差异表达基因,并将其缩小到80个lncrna,这些lncrna在4种以上癌症类型中普遍表达。使用Pearson’s correlation和肿瘤免疫评分系统检测这些lncrna与免疫反应相关基因的关系。通过使用QuanTIseq对具有肿瘤浸润淋巴细胞(TIL)状态的高分lncrna进行受试者工作特征(ROC)分析,并使用多变量Cox比例风险模型进行癌症预后分析。结果:对80个lncRNA基因与免疫应答相关基因进行相关性分析,基于肿瘤免疫状态评分算法(TIMMUSCORA)对lncRNA基因进行评分,并将lncRNA基因分为免疫状态高、中、低评分组。对评分较高(>200)的lncRNA基因进行ROC分析,发现其对CD8+ T细胞、B细胞等TILs的识别灵敏度较高。此外,80个lncRNA基因中有11个被鉴定为预后基因。结论:12个免疫状态评分较高的lncRNA基因被鉴定为免疫原性基因和CD8+ T细胞浸润相关基因,其中2个为肿瘤阳性预后指标。这些结果表明,具有高免疫状态评分的12个lncRNA基因可能作为与阳性免疫反应和预后相关的免疫原性生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Anticancer research
Anticancer research 医学-肿瘤学
CiteScore
3.70
自引率
10.00%
发文量
566
审稿时长
2 months
期刊介绍: ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信